NEO - CIK 0001077183
NEOGENOMICS INC trades as NEO and has a market capitalization of $1.49 B, making it the #2325 largest US-listed company by market value. This page tracks NEOGENOMICS INC through 1,246 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-07 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
NeoGenomics Reports First Quarter 2026 Results :: NeoGenomics, Inc. (NEO)
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types :: NeoGenomics, Inc. (NEO)
The largest companies sharing NEOGENOMICS INC's SEC industry classification (services-testing laboratories).
NEOGENOMICS INC (NEO) has a market capitalization of $1.49 B as of 2026-06-10, ranking #2325 among US-listed companies.
In its latest fiscal year NEOGENOMICS INC reported a net loss of $108.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.